Bipolar Disorder
📧 Sign up to get email alerts when something new happens for Bipolar Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-05-08FDA Approved: LITHIUM CARBONATE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a supplemental application for lithium carbonate from Glenmark Pharmaceuticals Inc., USA, indicating approval of changes to the…
-
FDA approval · 2023-05-01FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Par Health USA, LLC)
FDA announces a supplemental approval for a generic fixed-dose combination of olanzapine and fluoxetine by Par Health USA, LLC under ANDA 07…
-
FDA approval · 2023-04-28FDA Approved: UZEDY — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approved UZEDY (risperidone) through an original application from Teva Pharmaceuticals USA, Inc. for the treatment of schizophrenia, bip…
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: Feasibility Electrical Stimulation Study for Visual Hallucinations [NA]
A completed feasibility study evaluating electrical stimulation for visual hallucinations in schizophrenia, schizoaffective disorder, and bi…
-
FDA approval · 2023-04-20FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Ingenus Pharmaceuticals, LLC)
FDA approved a supplemental application for quetiapine fumarate from Ingenus Pharmaceuticals, LLC, marking an additional approval/modificati…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-04-19FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for quetiapine fumarate from Aurobindo Pharma Limited, authorizing a generic version under an ANDA.
-
FDA approval · 2023-04-19FDA Approved: QUETIAPINE — Supplemental Application (Solco Healthcare U.S., LLC)
FDA approved a supplemental application for quetiapine from Solco Healthcare U.S., LLC to authorize a generic version of the drug for the U.…
-
FDA approval · 2023-03-24FDA Approved: CARBAMAZEPINE — Original Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA's original ANDA for carbamazepine (generic anticonvulsant). This marks the availability of a generic carbamaz…
-
CLINICAL_TRIALS trial_result · 2023-03-23Clinical Trial Update: Skills Training to Enhance Vocational Outcomes in Veterans With Serious Mental Illness [NA]
Completed clinical trial evaluating skills training to improve vocational outcomes in veterans with serious mental illness; results posted i…
-
FDA approval · 2023-03-22FDA Approved: OLANZAPINE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original application for a generic olanzapine product. The approval enables marketing of the olanzapine…
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders [Phase 2]
Phase 2 trial evaluating the effects of erythropoietin on cognition and neural activity in mood disorders has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-03Clinical Trial Update: DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder [Phase 4]
A Phase 4 clinical trial on carbamazepine (Equetro) for maintenance in children with acute manic or mixed bipolar disorder has been terminat…
-
FDA approval · 2023-03-02FDA Approved: CARBAMAZEPINE ER — Original Application (Epic Pharma, LLC)
FDA approves the first original-application generic Carbamazepine ER from Epic Pharma, LLC under ANDA 216235. This extended-release formulat…
-
FDA approval · 2023-02-24FDA Approved: DEPAKOTE SPRINKLES — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for Depakote Sprinkles (divalproex sodium) submitted by AbbVie Inc.
-
FDA approval · 2023-02-24FDA Approved: DEPAKOTE ER — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for Depakote ER (divalproex sodium) submitted by AbbVie, expanding the NDA with additional regul…
-
FDA approval · 2023-02-24FDA Approved: OLANZAPINE — Original Application (Modavar Pharmaceuticals LLC)
The FDA approved Modavar Pharmaceuticals LLC's original application for olanzapine, a generic antipsychotic. It is approved for the treatmen…
-
FDA approval · 2023-02-10FDA Approved: OLANZAPINE — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for olanzapine from Dr. Reddy's Laboratories Limited (ANDA 076534), authorizing a generic olanzapine…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Trehalose as add-on Therapy in Bipolar Depression [Phase 3]
Phase 3 trial updating trehalose as add-on therapy in bipolar depression has completed.
-
FDA approval · 2023-01-31FDA Approved: ARIPIPRAZOLE — Supplemental Application (VistaPharm, LLC)
FDA approved a supplemental application for aripiprazole filed by VistaPharm, LLC, marking approval of a supplemental submission for this ge…
-
FDA approval · 2023-01-25FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approves a supplemental application for divalproex sodium submitted by Ajanta Pharma USA Inc.
-
CLINICAL_TRIALS trial_result · 2023-01-19Clinical Trial Update: Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder [Phase 3]
A Phase 3 trial evaluating ALKS 3831 for body weight effects in young adults recently diagnosed with schizophrenia, schizophreniform disorde…
-
FDA approval · 2023-01-13FDA Approved: RYKINDO EXTENDED-RELEASE MICROSPHERES — Original Application (Shandong Luye Pharmaceutical Co., Ltd.)
FDA approved RYKINDO EXTENDED-RELEASE MICROSPHERES, an oral extended-release formulation of risperidone from Shandong Luye Pharmaceutical, u…
-
FDA approval · 2023-01-05FDA Approved: LITHIUM CARBONATE LITHIUM CARBONATE — Supplemental Application (Alembic Pharmaceuticals Inc.)
The FDA approved a supplemental application for lithium carbonate from Alembic Pharmaceuticals Inc., signaling approval for an existing gene…
-
CLINICAL_TRIALS trial_result · 2022-12-30Clinical Trial Update: Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study [NA]
A completed clinical trial evaluating transcranial magnetic stimulation targeting the cerebellum for schizophrenia-related psychosis with re…
-
FDA approval · 2022-12-27FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for divalproex sodium from Aurobindo Pharma Limited.